Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy

Antimicrobial Agents and Chemotherapy - Tập 46 Số 6 - Trang 1896-1905 - 2002
Xiping Wei1, Julie M. Decker1, Hongmei Liu2,3, Zee Zhang2,3, Ramin B. Arani4, J Michael Kilby2,3, Michael S. Saag2,3, Xiaoyun Wu2,3, George M. Shaw1,2,3, John C. Kappes4,5,2
1Howard Hughes Medical Institute, Departments of
2Medicine
3Microbiology
4Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama 35294
5Birmingham Veterans Affairs Medical Center, Research Service, Birmingham, Alabama 35233

Tóm tắt

ABSTRACT The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compounds to demonstrate in vivo potency by targeting a step in viral entry. T-20 inhibits a conformational change in the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein (gp41) that is required for fusion between HIV-1 and target cell membranes. The initial phase I clinical trial of T-20 treatment for HIV-infected patients thus provided a unique opportunity to evaluate the emergence of resistant virus in vivo to this novel class of antiretroviral agents. All four patients who received an intermediate dose of T-20 (30 mg twice daily) had an initial decline in plasma viral load over the first 10 days but a rising trend by day 14, suggestive of selection for resistant virus. Plasma virus derived from patients enrolled in all dosage groups of the phase I T-20 trial was analyzed by population sequencing before and after treatment. While no mutations were found within a highly conserved 3-amino-acid sequence (GIV) known to be critical for fusion at baseline, after 14 days of therapy, virus from one patient in the 30-mg dose group (30-1) developed a mutation in this motif, specifically an aspartic acid (D) substitution for glycine (G) at position 36. Multiple env clones were derived from the plasma virus of all four patients in the 30-mg dosage group. Sequence analysis of 49 clones derived from the plasma of patient 30-1 on day 14 revealed that 25 clones contained the G36D mutation, while 8 contained the V38A mutation. Dual mutations involving G36D and other residues within the HR1 domain were also identified. In 5 of the 49 env clones, other mutations involving residues 32 (Q32R or Q32H) and 39 (Q39R) were found in combination with G36D. Cloned env sequences derived from the plasma virus of subject 30-3 also had single mutations in the GIV sequence (V38M and I37V) detectable following therapy with T-20. The plasma virus from subjects 30-2 and 30-4 did not contain changes within the GIV sequence. To analyze the biological resistance properties of these mutations, we developed a novel single-cycle HIV-1 entry assay using JC53BL cells which express β-galactosidase and luciferase under control of the HIV-1 long terminal repeat. Full-length env clones were derived from the plasma virus of patients 30-1 and 30-3 and used to generate pseudotyped virus stocks. The mean 50% inhibition concentrations (IC 50 s) for mutants G36D and V38A (patient 30-1) were 2.3 μg/ml and 11.2 μg/ml, respectively, statistically significant increases of 9.1- and 45-fold, respectively, compared with those of wild-type Env. The IC 50 for the V38 M mutation (patient 30-3) was 7.6 μg/ml, an 8-fold increase compared with that of the wild type. The I37V mutation resulted in an IC 50 3.2-fold greater than that of the wild type. Envs with double mutations (Q32R plus G36D and Q32H plus G36D) exhibited a level of resistance similar to that of G36D alone. These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents.

Từ khóa


Tài liệu tham khảo

10.1128/jvi.59.2.284-291.1986

10.1016/S0092-8674(00)80205-6

10.1128/jvi.69.6.3771-3777.1995

10.1038/374569a0

10.1128/JVI.75.18.8605-8614.2001

10.1128/JVI.74.18.8358-8367.2000

10.1073/pnas.88.6.2189

Hunter, E. 1997. Viral entry and receptors, p. 71-120. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

10.1038/365113a0

10.1038/3293

Kilby J. M. J. P. Lalezari J. J. Eron M. Carlson C. Cohen R. C. Arduino J. C. Goodgame J. E. Gallant P. Volberding R. L. Murphy F. Valentine M. S. Saag E. L. Nelson P. R. Sista and A. Dusek. The safety plasma pharmacokinetics and antiviral activity of subcutaneous enfuvirtide (T-20) a peptide inhibitor of gp41-mediated virus fusion in HIV-infected adults. AIDS Res. Hum. Retrovir. in press.

10.1128/jvi.65.8.3973-3985.1991

10.1038/nsb1295-1075

10.1126/science.2251501

10.1126/science.272.5259.263

10.1128/JVI.72.4.2855-2864.1998

10.1128/JVI.72.2.986-993.1998

10.1056/NEJM199310073291502

10.1084/jem.174.2.407

10.1098/rstb.1993.0136

10.1093/infdis/171.6.1411

10.1128/jvi.69.7.4413-4422.1995

10.1038/373117a0

10.1038/387426a0

10.1089/aid.1993.9.1051

10.1073/pnas.89.21.10537

10.1073/pnas.91.21.9770

10.1093/emboj/16.16.5113